<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535715</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20140476H</org_study_id>
    <nct_id>NCT02535715</nct_id>
  </id_info>
  <brief_title>A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)</brief_title>
  <official_title>A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORAMED has developed an oral insulin that, in preliminary studies, has shown promise. In the
      present study investigators will perform a pharmacodynamic/pharmacokinetic study to evaluate
      this novel insulin preparation as a potential therapeutic option in diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin therapy is an absolute requirement in type 1 diabetic patients. Multiple injections
      present a barrier to achieving normal/near-normal glucose control in diabetic patients (1).
      Therefore, there has been considerable interest in developing alternative routes of insulin
      administration. ORAMED has developed an oral insulin that, in preliminary studies, has shown
      promise. In the present study investigators will perform a pharmacodynamic/pharmacokinetic
      study to evaluate this novel insulin preparation as a potential therapeutic option in type 1
      diabetic patients.

      10 type 1 diabetic subjects will be studied.

      Each subject will be studied on three occasions with an interval of 3 days to 4 weeks between
      each study. During each study subjects will receive one intervention at a time in random
      order: (i) two 8 mg ORAMED capsule containing insulin; (ii) three 8 mg ORAMED capsules
      containing insulin; (iii) one 16 mg ORAMED capsule containing insulin. If the fasting plasma
      glucose is &gt;200mg/dl on the procedure day, the procedure will be rescheduled.

      Prior to each study subjects will refrain from eating (except water) after 10 at night and
      report to the Clinical Research Center at approximately 7 in the morning. A catheter will be
      placed in an antecubital vein and a prime (40 microCuries x fasting plasma glucose/100) -
      continuous (0.4 microCuries/min) infusion of tritiated glucose will be started and continued
      until the end of the study. Plasma glucose will be monitored and if necessary during the 1st
      hour of tracer equilibration, a small amount of IV regular insulin will be administered to
      obtain a fasting plasma glucose of 100-130mg/dl. After a 3-hour tracer equilibration,
      subjects will ingest the ORAMED capsule containing insulin and a variable infusion of 20%
      glucose will be started to maintain the plasma glucose concentration between 100-120 mg/dl.
      Plasma samples for glucose, insulin, glucagon, and free fatty acid (FFA) concentrations and
      tritiated glucose radioactivity will be obtained every 5-15 minutes for 4 hours following the
      ingestion of the ORAMED capsule containing insulin.

      Calculations: Following an overnight fast, steady state conditions prevail and the basal rate
      of glucose appearance equals the rate of glucose disappearance and is calculated as the
      tritiated glucose infusion rate divided by the tritiated glucose specific activity. Under
      postabsorptive conditions, Basal rate of glucose appearance primarily reflects hepatic
      glucose production (2). Following the ingestion of oral insulin, non-steady state conditions
      prevail and Ra and Rd are calculated using Steele's equation (3). Endogenous (primarily
      reflects liver) glucose production is calculated by subtracting the exogenous glucose
      infusion rate from the tracer-derived rate of glucose appearance. Endogenous rate of glucose
      disappearance reflects glucose uptake by all tissues in the body, but primarily reflects
      skeletal muscle (4).

      Sample Size: The present study represents a pilot study to gain information about the
      absorption of oral insulin and its effect on hepatic and peripheral (skeletal muscle) glucose
      metabolism. This information will be used to determine whether the ORAMED oral insulin
      preparation represents a viable option to treat diabetic subjects, to gain information about
      the dose response effect of ORAMED insulin on glucose metabolism, and to provide quantitative
      data about the effect of oral insulin on hepatic and peripheral (muscle) glucose metabolism.
      Therefore, the investigators conservatively have set the sample size at 10.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Glucose Production (Co-primary Outcome)</measure>
    <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
    <description>Tritiated glucose infusion during procedures (Baseline and every 30 minutes during procedures) Calculated from plasma(mg/kg-minute). Averaged every 30 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin Concentrations</measure>
    <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
    <description>Baseline and every 15 minutes during procedures (microIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Concentrations</measure>
    <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
    <description>Measured at baseline and every 5 minutes during the procedures(mg/dL), Averaged over 30 minute intervals during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon Concentrations</measure>
    <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
    <description>Measured at baseline and every 30 minutes during the procedures (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Free Fatty Acid Concentrations</measure>
    <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
    <description>Measured at baseline and every 30 minutes during the procedures (micro mol/L)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 capsules- 2x8mg</intervention_name>
    <description>Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
    <arm_group_label>ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd</arm_group_label>
    <other_name>Oral Insulin Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 capsules- 3x8mg</intervention_name>
    <description>Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
    <arm_group_label>ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd</arm_group_label>
    <other_name>Oral Insulin Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 capsules- 1x16mg</intervention_name>
    <description>Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
    <arm_group_label>ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd</arm_group_label>
    <arm_group_label>ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd</arm_group_label>
    <other_name>Oral Insulin Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be between 18 and 70 years of age

          -  Must have type 1 diabetes

          -  Must be in good general health by routine history and physical exam

          -  A1c &lt;10.0%

          -  BMI = 18-40 kg/m2

          -  On no medications known to affect glucose metabolism other than insulin

          -  Hematocrit ≥ 34 vol%

          -  Liver Function Tests &lt; 3 x Upper Normal Limit

          -  Plasma creatinine &lt; 1.8 mg/dl

        Exclusion Criteria:

          -  Under 18 years of age and over 70 years of age

          -  Does not have type 1 diabetes

          -  A1c &gt; 10.0%

          -  BMI &lt; 18 or &gt; 40 kg.m2

          -  On medications known to affect glucose metabolism other than insulin

          -  Hematocrit ≤ 34 vol%

          -  Liver Function Tests &gt;3 x Upper Normal Limit

          -  Plasma creatinine &gt; 1.8 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005 Oct;28(10):2543-5.</citation>
    <PMID>16186296</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989 Apr;38(4):387-95.</citation>
    <PMID>2657323</PMID>
  </reference>
  <reference>
    <citation>STEELE R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959 Sep 25;82:420-30.</citation>
    <PMID>13833973</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02535715/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects will be assigned to all 3 interventions during the study. One intervention will be assigned at a time, but in random order, with a 3 day to 4 week interval between interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2 x 8mg Oral Insulin Capsules</title>
          <description>Subject enrolled in study who will be assigned to different interventions for the 3 periods of the study with a 3 day to 4 week interval between the different interventions. For this arm, participants will receive the 2x8mg dose first.
2 x 8mg Oral Insulin Capsules 3 x 8mg Oral Insulin Capsules
1 x 16mg Oral Insulin Capsule</description>
        </group>
        <group group_id="P2">
          <title>3 x 8mg Oral Insulin Capsules</title>
          <description>Subject enrolled in study who will be assigned to different interventions for the 3 periods of the study with a 3 day to 4 week interval between the different interventions. For this arm, participants will receive the 3x8mg dose first.
2 x 8mg Oral Insulin Capsules 3 x 8mg Oral Insulin Capsules
1 x 16mg Oral Insulin Capsule</description>
        </group>
        <group group_id="P3">
          <title>1 X 16mg Oral Insulin Capsule</title>
          <description>Subject enrolled in study who will be assigned to different interventions for the 3 periods of the study with a 3 day to 4 week interval between the different interventions. For this arm, participants will receive the 1 x 16mg dose first.
2 x 8mg Oral Insulin Capsules 3 x 8mg Oral Insulin Capsules
1 x 16mg Oral Insulin Capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Type 1 Diabetes Mellitus subjects in good general health</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Two 8 mg ORAMED capsules containing insulin then Three 8mg ORAMED capsules containing insulin then One 16mg ORAMED capsules containing insulin
ORMD-0801 capsules: ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black-non Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Glucose Production (Co-primary Outcome)</title>
        <description>Tritiated glucose infusion during procedures (Baseline and every 30 minutes during procedures) Calculated from plasma(mg/kg-minute). Averaged every 30 minutes.</description>
        <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Two (2) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O2">
            <title>3X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Three (3) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O3">
            <title>1X 16mg Oral Insulin Capsules</title>
            <description>ORAMED provided 16mg oral insulin capsules. One(1) capsule administered at time 0 of the euglycemic clamp</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Glucose Production (Co-primary Outcome)</title>
          <description>Tritiated glucose infusion during procedures (Baseline and every 30 minutes during procedures) Calculated from plasma(mg/kg-minute). Averaged every 30 minutes.</description>
          <units>mg/kg-minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-180 to 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.1"/>
                    <measurement group_id="O2" value="2.0" spread="0.1"/>
                    <measurement group_id="O3" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.2"/>
                    <measurement group_id="O2" value="1.9" spread="0.1"/>
                    <measurement group_id="O3" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.7" spread="0.20"/>
                    <measurement group_id="O3" value="2.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                    <measurement group_id="O3" value="1.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>91-120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.7" spread="0.2"/>
                    <measurement group_id="O3" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>121-150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.6" spread="0.2"/>
                    <measurement group_id="O3" value="1.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>151-180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.6" spread="0.2"/>
                    <measurement group_id="O3" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181-210 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                    <measurement group_id="O3" value="1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>211-240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                    <measurement group_id="O3" value="1.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Insulin Concentrations</title>
        <description>Baseline and every 15 minutes during procedures (microIU/mL).</description>
        <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
        <population>Plasma insulin Concentrations were measured during each procedure in a type 1 DM population Analysis from one subject was not included: Results below threshold of assay</population>
        <group_list>
          <group group_id="O1">
            <title>Two 8mg ORAMED Capsules Containing Insulin</title>
            <description>Two (2) 8 mg ORAMED capsules containing insulin
ORMD-0801 capsules: ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
          </group>
          <group group_id="O2">
            <title>Three 8mg ORAMED Capsules</title>
            <description>Three (3) 8mg ORAMED INSULIN CAPSULES containing oral insulin</description>
          </group>
          <group group_id="O3">
            <title>One 16mg ORAMED Capsule</title>
            <description>One (1) 16mg ORAMED INSULIN CAPSULE containing oral insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Insulin Concentrations</title>
          <description>Baseline and every 15 minutes during procedures (microIU/mL).</description>
          <population>Plasma insulin Concentrations were measured during each procedure in a type 1 DM population Analysis from one subject was not included: Results below threshold of assay</population>
          <units>microUnits/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4"/>
                    <measurement group_id="O2" value="8" spread="8"/>
                    <measurement group_id="O3" value="7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="8" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="4"/>
                    <measurement group_id="O2" value="7" spread="6"/>
                    <measurement group_id="O3" value="7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>105 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="5"/>
                    <measurement group_id="O3" value="7" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>135 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="5"/>
                    <measurement group_id="O3" value="7" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="5"/>
                    <measurement group_id="O3" value="7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>165 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="5"/>
                    <measurement group_id="O3" value="6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>195 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="5"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="6" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>230 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="8" spread="6"/>
                    <measurement group_id="O3" value="7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="6"/>
                    <measurement group_id="O2" value="7" spread="6"/>
                    <measurement group_id="O3" value="7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Concentrations</title>
        <description>Measured at baseline and every 5 minutes during the procedures(mg/dL), Averaged over 30 minute intervals during the procedure</description>
        <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Two 8mg ORAMED Capsules Containing Insulin</title>
            <description>Two (2) 8 mg ORAMED capsules containing insulin
ORMD-0801 capsules: ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.</description>
          </group>
          <group group_id="O2">
            <title>Three 8mg ORAMED Capsules</title>
            <description>Three (3) 8mg ORAMED INSULIN CAPSULES containing oral insulin</description>
          </group>
          <group group_id="O3">
            <title>One 16mg ORAMED Capsule</title>
            <description>One (1) 16mg ORAMED INSULIN CAPSULE containing oral insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Concentrations</title>
          <description>Measured at baseline and every 5 minutes during the procedures(mg/dL), Averaged over 30 minute intervals during the procedure</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-180 to 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="9"/>
                    <measurement group_id="O2" value="120" spread="10"/>
                    <measurement group_id="O3" value="123" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="5"/>
                    <measurement group_id="O2" value="110" spread="8"/>
                    <measurement group_id="O3" value="115" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="5"/>
                    <measurement group_id="O2" value="113" spread="7"/>
                    <measurement group_id="O3" value="116" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="6"/>
                    <measurement group_id="O2" value="118" spread="8"/>
                    <measurement group_id="O3" value="116" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>91-120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="5"/>
                    <measurement group_id="O2" value="117" spread="9"/>
                    <measurement group_id="O3" value="115" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>121 to 150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="5"/>
                    <measurement group_id="O2" value="115" spread="8"/>
                    <measurement group_id="O3" value="118" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>151 to 180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="5"/>
                    <measurement group_id="O2" value="113" spread="8"/>
                    <measurement group_id="O3" value="120" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181 to 210 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="6"/>
                    <measurement group_id="O2" value="112" spread="9"/>
                    <measurement group_id="O3" value="122" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>210 to 240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" spread="7"/>
                    <measurement group_id="O2" value="117" spread="10"/>
                    <measurement group_id="O3" value="128" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucagon Concentrations</title>
        <description>Measured at baseline and every 30 minutes during the procedures (pg/mL)</description>
        <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
        <population>Glucagon measured by RIA kit, EMD Millipore.</population>
        <group_list>
          <group group_id="O1">
            <title>2X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Two (2) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O2">
            <title>3X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Three (3) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O3">
            <title>1X 16mg Oral Insulin Capsules</title>
            <description>ORAMED provided 16mg oral insulin capsules. One(1) capsule administered at time 0 of the euglycemic clamp</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucagon Concentrations</title>
          <description>Measured at baseline and every 30 minutes during the procedures (pg/mL)</description>
          <population>Glucagon measured by RIA kit, EMD Millipore.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-180 to 0 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="4"/>
                    <measurement group_id="O2" value="37" spread="4"/>
                    <measurement group_id="O3" value="37" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="4"/>
                    <measurement group_id="O2" value="38" spread="5"/>
                    <measurement group_id="O3" value="36" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="3"/>
                    <measurement group_id="O2" value="37" spread="4"/>
                    <measurement group_id="O3" value="34" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="3"/>
                    <measurement group_id="O2" value="36" spread="4"/>
                    <measurement group_id="O3" value="34" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>91-120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="4"/>
                    <measurement group_id="O2" value="34" spread="4"/>
                    <measurement group_id="O3" value="33" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>121-150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="3"/>
                    <measurement group_id="O2" value="35" spread="4"/>
                    <measurement group_id="O3" value="34" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>151-180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="4"/>
                    <measurement group_id="O2" value="35" spread="4"/>
                    <measurement group_id="O3" value="33" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181 to 210 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="3"/>
                    <measurement group_id="O2" value="35" spread="4"/>
                    <measurement group_id="O3" value="31" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>211-240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="3"/>
                    <measurement group_id="O2" value="36" spread="4"/>
                    <measurement group_id="O3" value="32" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Free Fatty Acid Concentrations</title>
        <description>Measured at baseline and every 30 minutes during the procedures (micro mol/L)</description>
        <time_frame>Participants will be followed during the procedures, until all 3 procedures are completed, an average of 1 month</time_frame>
        <population>Wako Calorometric</population>
        <group_list>
          <group group_id="O1">
            <title>2X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Two (2) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O2">
            <title>3X 8mg Oral Insulin Capsules</title>
            <description>ORAMED provided 8 mg oral insulin capsules. Three (3) capsules administered at time 0 of the euglycemic clamp</description>
          </group>
          <group group_id="O3">
            <title>1X 16mg Oral Insulin Capsules</title>
            <description>ORAMED provided 16mg oral insulin capsules. One(1) capsule administered at time 0 of the euglycemic clamp</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Free Fatty Acid Concentrations</title>
          <description>Measured at baseline and every 30 minutes during the procedures (micro mol/L)</description>
          <population>Wako Calorometric</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380" spread="68"/>
                    <measurement group_id="O2" value="402" spread="80"/>
                    <measurement group_id="O3" value="410" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408" spread="76"/>
                    <measurement group_id="O2" value="465" spread="81"/>
                    <measurement group_id="O3" value="467" spread="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463" spread="78"/>
                    <measurement group_id="O2" value="533" spread="96"/>
                    <measurement group_id="O3" value="448" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472" spread="74"/>
                    <measurement group_id="O2" value="545" spread="102"/>
                    <measurement group_id="O3" value="489" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>91-120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" spread="84"/>
                    <measurement group_id="O2" value="473" spread="94"/>
                    <measurement group_id="O3" value="506" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>121-150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528" spread="74"/>
                    <measurement group_id="O2" value="501" spread="97"/>
                    <measurement group_id="O3" value="509" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>151-180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547" spread="80"/>
                    <measurement group_id="O2" value="486" spread="95"/>
                    <measurement group_id="O3" value="545" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181-210 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523" spread="75"/>
                    <measurement group_id="O2" value="485" spread="97"/>
                    <measurement group_id="O3" value="533" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>211-240 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" spread="69"/>
                    <measurement group_id="O2" value="486" spread="95"/>
                    <measurement group_id="O3" value="538" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>ANOVA Bonferroni adjustment</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected over period of participation of each subject: From signing of informed consent, including between procedures, until conclusion of 3rd procedure. Subjects were instructed to call us if any adverse events after this timeframe.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2X 8mg Capsules</title>
          <description>Adverse event reporting for subjects during the 2X 8mg dosing regimen</description>
        </group>
        <group group_id="E2">
          <title>3X 8mg Oral Insulin Capsules</title>
          <description>Adverse event reporting for subjects during the 3X 8mg dosing regimen</description>
        </group>
        <group group_id="E3">
          <title>1X 16mg Capsules</title>
          <description>Adverse event reporting for subjects during the 1X 16mg dosing regimen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Curtis Triplitt, PharmD</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>210-358-7228</phone>
      <email>triplitt@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

